Oral Estradiol and Imaging Contrast Dye: What You Need to Know Before Your Scan

Is There a Direct Interaction Between Oral Estradiol and Contrast Dye?

No direct interaction is described between oral estradiol and iodinated contrast or gadolinium-based contrast. The oral estradiol label discusses drug interactions through CYP3A4: inducers such as St. John's wort, phenobarbital, carbamazepine and rifampin may lower estrogen levels, while inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise them [1]. Contrast dye is not among the examples the label names.

What the Label Says About Clot Risk

The oral estradiol label carries a boxed warning headed 'CARDIOVASCULAR AND OTHER RISKS' and warns about venous thrombosis and pulmonary embolism [1]. It also says that if feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization [1].

That statement is worded around surgery and prolonged immobilization.

Oral Versus Transdermal Estrogen: The VTE Data

Route matters in the venous thromboembolism data. In the ESTHER study, a French multicenter case-control study of women aged 45 to 70, current oral estrogen users had an adjusted odds ratio for first idiopathic VTE of 4.2 (95% CI 1.5 to 11.6) compared with nonusers; transdermal estrogen users had an odds ratio of 0.9 (95% CI 0.4 to 2.1) [2].

A 2008 BMJ systematic review and meta-analysis (eight observational studies and nine randomized trials) pooled the observational studies and found an odds ratio for first VTE of 2.5 (95% CI 1.9 to 3.4) with oral estrogen and 1.2 (95% CI 0.9 to 1.7) with transdermal estrogen [3]. These studies are observational and measured VTE, not contrast reactions.